Product overview
Retatrutide 30mg/10vials is a sterile lyophilized research peptide supplied at the higher-strength 30mg-per-vial configuration. Retatrutide is a synthetic single-molecule triple agonist at the GLP-1, GIP, and glucagon receptors, and is one of the most-studied recent additions to the incretin-mimetic family in preclinical metabolic research.
Independently assayed by HPLC and MS, and lot-traceable to the source preparation. The 30mg-per-vial format sits between the RT20 (20mg) and RT40 (40mg) configurations for research protocols that require an intermediate working volume.
Typical research dose range
Published preclinical and early clinical metabolic protocols have used Retatrutide across a range of weekly exposure. Animal-model and early-stage clinical research has used per-administration quantities scaling with body mass, with weekly cycling that mirrors the once-weekly dosing pattern characteristic of the incretin-mimetic class. Researchers should consult source literature for the specific endpoint and model organism.
Stack and pairing
Retatrutide is studied alongside Tirzepatide for receptor-coverage comparison work, and is included in protocols examining combined incretin-axis and hepatic-metabolism endpoints. It is also paired with glutathione preparations in study designs that include redox-balance measurements.
Reconstitution and storage
Reconstitute each vial with 1-3 mL of bacteriostatic water for the target working concentration. Use sterile technique. Once reconstituted, store at 2-8 °C and use within 30 days for best stability.
Lyophilized vials should be kept refrigerated at 2-8 °C until first use. For long-term storage beyond six months, store at -20 °C in the original sealed vial. Avoid repeated freeze-thaw cycles.
Kit contents
- 10 × 30mg vials of lyophilized Retatrutide
- 1 × certificate of analysis (lot-specific)
- 1 × handling and reconstitution insert
